Share market : कोविड महामारी से जुड़ी गतिविधियों, वैश्विक प्रवृत्ति से तय होगी बाजार की चाल punjabkesari.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from punjabkesari.com Daily Mail and Mail on Sunday newspapers.
MSN Labs inks pact with Eli Lilly to make, market COVID drug Baricitinib
Updated:
Updated:
Share Article
AAA MSN Labs has joined a small, but growing list of drugmakers in India with whom US pharma giant Eli Lilly has got into royalty free, non-exclusive, voluntary license agreements for manufacture and marketing of Baricitinib, a drug used to treat COVID-19.
A statement from MSN on May 13, announcing the signing of the agreement, said the Hyderabad-based company will be launching the product under the brand name Baridoz in two strengths 2 mg and 4 mg. MSN has developed the active pharmaceutical ingredient and the formulation of baricitinib in its in-house research and development and manufacturing units, it said.
A debate has broken out over the safety and efficacy of the drug Ivermectin after Goa’s Health Minister Vishwajit Rane announced that all adults (18 and above) be given the medicine as prophylaxis to bring down mortality amid a surge in Covid cases. Scientists and doctors, including the World Health Organisation (WHO), have advised against the use of Ivermectin for Covid. Soumya Swaminathan, chief scientist, WHO, said, “Safety and efficacy are important when using any drug for a new indication. WHO recommends against the use of ivermectin for Covid-19 except within clinical trials.” Rane had said that expert panels from the UK, Italy, Spain and Japan found a large, statistically significant reduction in mortality, time to recovery and viral clearance in Covid-19 patients treated with Ivermectin. “This does not prevent Covid-19 infection but helps in reducing the severity of the disease and at the same time one should not have a false sense of security and complacency but
US pharma giant Eli Lilly has issued royalty-free, non-exclusive voluntary licences to three Indian drug makers – Cipla, Sun Pharmaceuticals and Lupin – to manufacture and distribute Baricitinib, which is being used to treat Covid-19.
Earlier, Gilead too had signed non-exclusive voluntary licensing agreements with Indian pharmaceutical companies to expand the production of Remdesivir, a widely used anti-Covid drug.
“The voluntary licensing agreements will ensure high-quality manufacturing and accessibility of Baricitinib during this pandemic, improving the local treatment options available to positively impact the lives of people who are currently battling Covid-19 in India,” Eli Lilly said in a statement. The firm added that discussions were also taking place with other Indian players for the grant of voluntary licences to manufacture Baricitinib, which has recently found favour among clinicians for the treatment of Covid-19.